Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of Simmerafil (TPN171H) in Erectile Dysfunction
NCT05388825Phase 2Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Aug 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sildenafil in erectile dysfunction (ED) (6 arms), sponsored by Vigonvita Life Sciences. Primary endpoint: Duration of penile erections of greater than or equal to 60% rigidity at 60 minutes. Started Aug 2022; status: completed.
02
Drugs
sildenafil
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT05388825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388825.